NASDAQ: HSCSHeart Test Laboratories Inc Stock
$0.10+0.00 (+0%)
Updated Apr 23, 2024
HSCS Price
$0.10
Fair Value Price
$0.01
Market Cap
$6.49M
52 Week Low
$0.09
52 Week High
$1.32
P/E
-0.21x
P/B
0.75x
P/S
433.24x
PEG
N/A
Dividend Yield
N/A
Revenue
$18.60k
Earnings
-$6.39M
Gross Margin
67.3%
Operating Margin
-32,388.74%
Profit Margin
-34,362.4%
Debt to Equity
0.25
Operating Cash Flow
-$6M
Beta
-0.16
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
HSCS Overview
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional 12-lead resting ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how HSCS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
HSCS ($0.10) is overvalued by 772.98% relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
HSCS ($0.10) is not significantly undervalued (772.98%) relative to our estimate of its Fair Value price of $0.01 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
HSCS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more HSCS due diligence checks available for Premium users.
Be the first to know about important HSCS news, forecast changes, insider trades & much more!
HSCS News
Valuation
HSCS fair value
Fair Value of HSCS stock based on Discounted Cash Flow (DCF)
Price
$0.10
Fair Value
$0.01
Overvalued by
781.80%
HSCS ($0.10) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
HSCS ($0.10) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
HSCS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
HSCS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.21x
Industry
29.66x
Market
41.92x
HSCS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.75x
Industry
3.71x
HSCS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
HSCS's financial health
Profit margin
Revenue
$14.7k
Net Income
-$1.6M
Profit Margin
-11,182.4%
HSCS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
HSCS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$10.8M
Liabilities
$2.2M
Debt to equity
0.25
HSCS's short-term assets ($8.69M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HSCS's short-term assets ($8.69M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HSCS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.1M
Investing
-$8.8k
Financing
$9.1M
HSCS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
HSCS vs Medical Device Stocks
Heart Test Laboratories Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.